Results 51 to 60 of about 36,163 (246)
Advanced Healthcare Materials, EarlyView.We developed a novel copper‐doped aluminum nano‐adjuvant (CuNA) to overcome cytarabine resistance in acute myeloid leukemia (AML). CuNA effectively sensitizes drug‐resistant AML cells to cytarabine by inducing mitochondrial dysfunction and inhibiting HMGCR/GPX4 to amplify ferroptosis.
Chao He +10 more
wiley +1 more source
Review: Therapeutic approaches for lysosomal storage diseases
Therapeutic Advances in Endocrinology and Metabolism, 2010 The lysosomal storage disorders (LSDs) comprise a heterogeneous group of inborn errors of metabolism characterized by tissue substrate deposits, most often caused by a deficiency of the enzyme normally responsible for catabolism of various byproducts of ...
Gregory M. Pastores
doaj +1 more source
Isolation Defines Identity: Functional Consequences of Extracellular Vesicle Purification Strategies
Advanced Healthcare Materials, EarlyView.Four extracellular vesicle purification strategies are compared using ovarian‐cancer ascites and ES‐2 cell supernatants. A novel workflow links purification to function by combining particle‐normalized proteomics with matched cell‐free and cell‐based assays.
Christian Preußer +10 more
wiley +1 more source
Golgi defect as a major contributor to lysosomal dysfunction
Frontiers in Cell and Developmental BiologyThe Golgi apparatus plays a crucial role in lysosome biogenesis and the delivery of lysosomal enzymes, essential for maintaining cellular homeostasis and ensuring cell survival. Deficiencies in Golgi structure and function can profoundly impact lysosomal
Sarah R. Akaaboune, Yanzhuang Wang
doaj +1 more source
Lysosomal acid lipase deficiency in a 6-year-old child: case report
Archives of the Balkan Medical Union, 2020 Introduction. Cholesteryl ester storage disease or lysosomal acid lipase deficiency is a rare severe congenital enzyme pathology of lysosomal storage disorders.
Oleksandra SHULHAI +2 more
doaj +1 more source
Advanced Healthcare Materials, EarlyView.The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang +13 more
wiley +1 more source
From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function
Advanced Healthcare Materials, EarlyView.The evolution of lipid nanoparticles (LNPs) spans from RNA‐LNPs, used in mRNA vaccines, to DNA‐LNPs, ideal for gene therapies. Emerging bionano architectures, decorated with DNA and plasma proteins, pave the way for advanced DNA‐based therapies that are more stable, targeted, and customizable.
Erica Quagliarini +2 more
wiley +1 more source
The Link Between Lysosomal Storage Disorders and More Common Diseases
Journal of Inborn Errors of Metabolism and Screening, 2016 In the last decades, it has become more and more evident that lysosomal storage disorders and common neurodegenerative diseases such as Alzheimer and Parkinson diseases have clinical, neuropathological, and genetic features in common, including lysosomal
Michael Beck MD
doaj +1 more source
Lysosomal exocytosis and lipid storage disorders
Journal of Lipid Research, 2014 Lysosomes are acidic compartments in mammalian cells that are primarily responsible for the breakdown of endocytic and autophagic substrates such as membranes, proteins, and lipids into their basic building blocks. Lysosomal storage diseases (LSDs) are a
Mohammad Ali Samie, Haoxing Xu
doaj +1 more source
Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases
Frontiers in Molecular Biosciences, 2020 There are over 50 lysosomal hydrolase deficiencies, many of which cause neurodegeneration, cognitive decline and death. In recent years, a number of broad innovative therapies have been proposed and investigated for lysosomal storage diseases (LSDs ...
Jacob M. Favret +3 more
doaj +1 more source